A systematic review of the drug-drug interaction between Statins and Quinolones.
Drug interaction
Quinolones
Rhabdomyolysis
Statins
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
received:
20
06
2023
accepted:
23
06
2024
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
10
7
2024
Statut:
epublish
Résumé
Statins are widely used in cardiovascular disease (CVD) as a common lipid-lowering drug, while quinolones are widely used for the treatment of infectious diseases. It is common to see CVD in combination with infectious diseases, therefore it is often the case that statins and quinolones are used in combination. Data suggest combinations of statin and quinolone may be associated with potentially life-threatening myopathy, rhabdomyolysis and acute hepatitis. This systematic review aims to characterize data regarding patients affected by the statin-quinolone interaction. The purpose of this systematic review was to collect and evaluate the evidence surrounding statin-quinolone drug interactions and to discuss related risk mitigation strategies. The following databases were searched: PubMed (Medline), Embase, Scopus, and Cochrane Library. The systematic electronic literature search was conducted with the following search terms. In this study, three types of search terms were used: statins-related terms, quinolones-related terms, and drug interactions-related terms. There were 16 case reports that met the criteria for qualitative analysis. Patients were involved in the following adverse reactions: rhabdomyolysis (n = 12), acute hepatitis (n = 1), muscle weakness (n = 1), hip tendinopathy (n = 1), or myopathy (n = 1). In the included literature, patients vary in the dose and type of statins they take, including simvastatin (n = 10) at a dose range of 20-80 mg/d and atorvastatin (n = 4) at a dose of 80 mg/d. There were 2 patients with unspecified statin doses, separately using simvastatin and atorvastatin. The quinolones in combination were ciprofloxacin (n = 9) at a dose range of 800-1500 mg/d, levofloxacin (n = 6) at a dose range of 250-1000 mg/d, and norfloxacin (n = 1) in an unspecified dose range. 81% of the case patients were over 60 years of age, and about 1/3 had kidney-related diseases such as diabetic nephropathy, post-transplantation, and severe glomerulonephritis. Nearly two-third of the patients were on concomitant cytochrome P450 3A4 (CYP3A4) inhibitors, P-glycoprotein (P-gp) inhibitors, or organic anion transporting polypeptide 1B1 (OATP1B1) inhibitors. Patients treated with statin-quinolone combination should be monitored more closely for changes in aspartate aminotransferase or creatine kinase (CK) levels, and muscle symptoms, especially in patients with ciprofloxacin or levofloxacin, with simvastatin and high-dose atorvastatin, over 60 years of age, with kidney-related diseases, and on concomitant CYP3A4 inhibitors.
Sections du résumé
BACKGROUND
BACKGROUND
Statins are widely used in cardiovascular disease (CVD) as a common lipid-lowering drug, while quinolones are widely used for the treatment of infectious diseases. It is common to see CVD in combination with infectious diseases, therefore it is often the case that statins and quinolones are used in combination. Data suggest combinations of statin and quinolone may be associated with potentially life-threatening myopathy, rhabdomyolysis and acute hepatitis. This systematic review aims to characterize data regarding patients affected by the statin-quinolone interaction.
METHODS
METHODS
The purpose of this systematic review was to collect and evaluate the evidence surrounding statin-quinolone drug interactions and to discuss related risk mitigation strategies. The following databases were searched: PubMed (Medline), Embase, Scopus, and Cochrane Library. The systematic electronic literature search was conducted with the following search terms. In this study, three types of search terms were used: statins-related terms, quinolones-related terms, and drug interactions-related terms.
RESULTS
RESULTS
There were 16 case reports that met the criteria for qualitative analysis. Patients were involved in the following adverse reactions: rhabdomyolysis (n = 12), acute hepatitis (n = 1), muscle weakness (n = 1), hip tendinopathy (n = 1), or myopathy (n = 1). In the included literature, patients vary in the dose and type of statins they take, including simvastatin (n = 10) at a dose range of 20-80 mg/d and atorvastatin (n = 4) at a dose of 80 mg/d. There were 2 patients with unspecified statin doses, separately using simvastatin and atorvastatin. The quinolones in combination were ciprofloxacin (n = 9) at a dose range of 800-1500 mg/d, levofloxacin (n = 6) at a dose range of 250-1000 mg/d, and norfloxacin (n = 1) in an unspecified dose range. 81% of the case patients were over 60 years of age, and about 1/3 had kidney-related diseases such as diabetic nephropathy, post-transplantation, and severe glomerulonephritis. Nearly two-third of the patients were on concomitant cytochrome P450 3A4 (CYP3A4) inhibitors, P-glycoprotein (P-gp) inhibitors, or organic anion transporting polypeptide 1B1 (OATP1B1) inhibitors.
CONCLUSION
CONCLUSIONS
Patients treated with statin-quinolone combination should be monitored more closely for changes in aspartate aminotransferase or creatine kinase (CK) levels, and muscle symptoms, especially in patients with ciprofloxacin or levofloxacin, with simvastatin and high-dose atorvastatin, over 60 years of age, with kidney-related diseases, and on concomitant CYP3A4 inhibitors.
Identifiants
pubmed: 38987799
doi: 10.1186/s40360-024-00760-8
pii: 10.1186/s40360-024-00760-8
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Quinolones
0
Anti-Bacterial Agents
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Informations de copyright
© 2024. The Author(s).
Références
Collins R, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61.
doi: 10.1016/S0140-6736(16)31357-5
pubmed: 27616593
Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743.
doi: 10.1136/bmj.g3743
pubmed: 25035309
pmcid: 4707717
Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord. 2014;24(1):4–15.
doi: 10.1016/j.nmd.2013.09.011
pubmed: 24176465
Penson PE, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the international lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13(3):1596–622.
doi: 10.1002/jcsm.12960
pubmed: 35969116
pmcid: 9178378
Bytyci I, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–23.
doi: 10.1093/eurheartj/ehac015
pubmed: 35169843
pmcid: 9757867
Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17(1):25–37.
doi: 10.1080/14740338.2018.1394455
pubmed: 29058944
Andriole VT. The quinolones: past, present, and future. Clin Infect Dis. 2005;41(Suppl 2):S113–9.
doi: 10.1086/428051
pubmed: 15942877
Majalekar PP, Shirote PJ. Fluoroquinolones: blessings or curses. Curr Drug Targets. 2020;21(13):1354–70.
doi: 10.2174/1389450121666200621193355
pubmed: 32564750
Grisold AJ, et al. Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis. J Infect Chemother. 2013;19(6):1214–7.
doi: 10.1007/s10156-013-0628-3
pubmed: 23744026
Gupta A, et al. Levofloxacin-induced rhabdomyolysis in a hemodialysis patient. Hemodial Int. 2012;16(1):101–3.
doi: 10.1111/j.1542-4758.2011.00592.x
pubmed: 22098607
Korzets A, et al. Levofloxacin and rhabdomyolysis in a renal transplant patient. Nephrol Dial Transpl. 2006;21(11):3304–5.
doi: 10.1093/ndt/gfl396
Ganske CM, Horning KK. Levofloxacin-induced tendinopathy of the hip. Ann Pharmacother. 2012;46(5):e13.
doi: 10.1345/aph.1Q635
pubmed: 22535840
Darnis D, et al. Be careful to the interaction between simvastatin and norfloxacin: an increased risk of rhabdomyolysis. Fundam Clin Pharmacol 2011;25.
Speck D, et al. A pulmonary mass caused by Rhodococcus equi infection in a renal transplant recipient. Nat Clin Pract Nephrol. 2008;4(7):398–403.
doi: 10.1038/ncpneph0833
pubmed: 18506169
Cowley E, Omar MA. Suspected Drug-Induced Rhabdomyolysis from the combination of atorvastatin, Amiodarone, and ciprofloxacin. Ann Pharmacother. 2021;55(3):415–6.
doi: 10.1177/1060028020946299
pubmed: 32762337
Irfan F, Karim SI. Co-prescription of ciprofloxacin and statins; a dangerous combination: Case Report. J Pak Med Assoc. 2020;70(7):1272–4.
pubmed: 32799291
Figueira-Coelho J, et al. Acute hepatitis associated with the use of levofloxacin. Clin Ther. 2010;32(10):1733–7.
doi: 10.1016/j.clinthera.2010.09.004
pubmed: 21194596
Goldie FC, Brogan A, Boyle JG. Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis. BMJ Case Rep, 2016. 2016.
Bouchard J, De La Pena N, Oleksiuk LM. Levofloxacin-induced rhabdomyolysis in a patient on concurrent atorvastatin: case report and literature review. J Clin Pharm Ther. 2019;44(6):966–9.
doi: 10.1111/jcpt.13010
pubmed: 31407828
Attaran-Bandarabadi M, et al. Weakness of the extremities in a 73-year-old male patient. Internist (Berl). 2016;57(8):815–8.
doi: 10.1007/s00108-016-0060-8
pubmed: 27167632
Paparoupa M, Pietrzak S, Gillissen A. Acute rhabdomyolysis associated with coadministration of levofloxacin and simvastatin in a patient with normal renal function. Case Rep Med. 2014;2014:562929.
doi: 10.1155/2014/562929
pubmed: 25140181
pmcid: 4129674
Bibi M, et al. When should statins be stopped? Eur J Case Rep Intern Med. 2021;8(7):002661.
pubmed: 34268273
pmcid: 8276924
De Schryver N et al. Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration. Case Rep Nephrol. 2015;2015:761393.
Sawant RD. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol. 2009;16(1):e78–9.
pubmed: 19151423
Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16(9):809–22.
doi: 10.1080/17425255.2020.1801634
pubmed: 32729746
Son H, et al. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. Drug Metab Pharmacokinet. 2014;29(2):120–8.
doi: 10.2133/dmpk.DMPK-13-RG-053
pubmed: 23965645
Zhou YT, et al. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management. Ther Clin Risk Manag. 2014;10:17–26.
pubmed: 24379677
Kasiske B, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transpl. 2004;4(Suppl 7):13–53.
doi: 10.1111/j.1600-6135.2004.0355.x
Holdaas H, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–31.
doi: 10.1016/S0140-6736(03)13638-0
pubmed: 12814712
Westphal JF. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50(4):285–95.
doi: 10.1046/j.1365-2125.2000.00261.x
pubmed: 11012550
pmcid: 2015000
Wiggins BS, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468–95.
doi: 10.1161/CIR.0000000000000456
pubmed: 27754879
Dall’Aglio A, et al. Rhabdomyolysis: early management. Rev Med Suisse. 2020;16(716):2272–8.
pubmed: 33237645
Sawhney JS, et al. Management of rhabdomyolysis: a practice management guideline from the Eastern Association for the surgery of Trauma. Am J Surg. 2022;224(1 Pt A):196–204.
doi: 10.1016/j.amjsurg.2021.11.022
pubmed: 34836603